RecruitingNot ApplicableNCT06101069

Development of MRF for Characterization of Brain Tumors After Radiotherapy

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy


Sponsor

Case Comprehensive Cancer Center

Enrollment

90 participants

Start Date

Oct 14, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study. The primary objectives of this study are: * To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage. * To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis. * To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is developing a new type of MRI brain scan technique called Magnetic Resonance Fingerprinting (MRF) to help doctors tell the difference between brain tumor recurrence and radiation damage — two conditions that look similar on standard imaging but require very different treatment approaches. **You may be eligible if...** - You are 21 years or older (for brain tumor patients) - You have had brain tumor treatment (radiation) and there is uncertainty about whether a new area on your scan is the tumor coming back or tissue damaged by radiation - Or you have a newly identified primary brain tumor (glioma) or brain metastases that has not yet been treated with radiation or surgery - You are in acceptable health (ECOG 0–2) with at least 6 months expected lifespan - Healthy volunteers with no history of brain disease and no cognitive impairment are also eligible **You may NOT be eligible if...** - You cannot undergo MRI scanning (metal implants, pacemakers, severe claustrophobia) - You have received prior radiation treatment for brain metastases or primary glioma (for the primary/metastases group) - Your general health or life expectancy does not meet the study requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMRF in conjunction with IVIM MRI without contrast

MRF in conjunction with IVIM MRI scan, without contrast.


Locations(2)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06101069


Related Trials